Preclinical studies using PLK1 inhibitors have demonstrated their efficacy in inhibiting tumor growth, inducing apoptosis, and sensitizing lung adenocarcinoma cells to conventional treatments. The gene discussed is PLK1; the disease is lung adenocarcinoma.